BamSEC and AlphaSense Join Forces
Learn More

Asterias Biotherapeutics, Inc.

Formerly NYSE American: AST

Material Contracts Filter

EX-10.1
from 10-Q 17 pages Sublease Agreement
12/34/56
EX-10.3
from 425 10 pages Amended and Restated Employment Agreement
12/34/56
EX-10.3
from 8-K 10 pages Amended and Restated Employment Agreement
12/34/56
EX-10.2
from 425 10 pages Amended and Restated Employment Agreement
12/34/56
EX-10.2
from 8-K 10 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 8-K 10 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 425 10 pages Amended and Restated Employment Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Amendment No. 1 to Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 5 pages 1. Placement Agent’s Fee. the Company Shall Pay to Chardan a Cash Placement Fee (The “Placement Agent’s Closing Fee”) Equal to Six Percent (6%) of the Aggregate Purchase Price Paid by Each Purchaser (The “Purchaser” or “Purchasers”) of Securities (Excluding Broadwood Partners, L.P (“Broadwood”) and Any Other Purchasers That Were Introduced to the Offering Through an Existing Relationship With the Company (Together With Broadwood, the "Existing Purchasers")), as to Which the Placement Agent’s Closing Fee Shall Be Equal to Three Percent (3%) of the Aggregate Purchase Price Paid by the Existing Purchasers). the Placement Agent’s Closing Fee Shall Be Due and Paid at the Closing of the Offering (The “Closing”) From the Gross Proceeds of the Securities Sold by the Company to the Purchasers (Excluding Any Proceeds From the Exercise of Warrants)
12/34/56
EX-10.1
from 8-K 31 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 5 pages May 23, 2017 Mr. Steve Cartt C/O Asterias Biotherapeutics, Inc. 6300 Dumbarton Circle, Fremont, Ca 94555 Re: Separation Agreement and Release of All Claims Dear Steve: 1. This Letter Will Confirm Our Agreement (“Agreement”) Concerning Your Separation From Employment With Asterias Biotherapeutics, Inc. (“Asterias” or “Company”)
12/34/56
EX-10.1
from 8-K 15 pages Employment Agreement
12/34/56
EX-10.24
from 10-K 6 pages Amendment No. 1 to at Market Issuance Sales Agreement
12/34/56
EX-10.1
from 8-K 12 pages Employment Agreement
12/34/56
EX-10.1
from 10-Q 69 pages Development and Manufacturing Services Agreement
12/34/56
EX-10.1
from 10-Q 23 pages 2013 Equity Incentive Plan
12/34/56
EX-10.35
from 10-K 4 pages March 9, 2016 Re: Separation Agreement and Release of All Claims Dear Georgia: 1. This Letter Will Confirm Our Agreement (“Agreement”) Concerning Your Separation From Employment With Asterias Biotherapeutics, Inc. (“Asterias” or “Company”). 2. Your Employment With Asterias Will Terminate on March 10, 2016. (“Separation Date”) Your Employment Agreement Will Also Terminate on Your Separation Date. Your Termination of Employment Will Be Treated as a Resignation. 3. There Is No Material Dispute Between the Parties. 4. Within Five (5) Business Days of the Effective Date of This Agreement, Asterias Will Pay You Severance in the Amount of $82,500, Less Withholding. 5. Within Five (5) Business Days of the Effective Date of This Agreement, Asterias Will Also Pay You $27,500, Less Withholding, Which Represents Your Total Potential Bonus Opportunity. 6. on Your Separation Date You Will Be Paid All Accrued but Unpaid Wages ($11,423.08) and Accrued but Unused Vacation ($6,598.57), All Less Withholding, Irrespective of Whether You Sign This Agreement
12/34/56
EX-10.34
from 10-K 2 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment Under Rule 24b-2 Under the Exchange Act of 1934, as Amended. Confidential Portions Are Marked: [***] Amendment to Notice of Award – Rfa 13-03a - Cirm Strategic Partnership III Track a Awards California Institute for Regenerative Medicine
12/34/56
EX-10.33
from 10-K 5 pages March 10, 2016 Pedro Lichtinger Re: Separation Agreement and Release of All Claims Dear Pedro: 1. This Letter Will Confirm Our Agreement (“Agreement”) Concerning Your Separation From Employment With Asterias Biotherapeutics, Inc. (“Asterias” or “Company”). 2. Your Employment With Asterias Terminated on February 29, 2016 at 12:01am Pacific Time. (“Separation Date”) Your Employment Agreement Terminated on Your Separation Date. 3. Within Five (5) Business Days of the Effective Date of This Agreement, Asterias Will Pay You Severance in the Amount of $226,200, Less Withholding. 4. Within Five (5) Business Days of the Effective Date of This Agreement, Asterias Will Also Pay You $248,800, Less Withholding, Which Represents Your Total Potential Bonus Opportunity. 5. on Your Separation Date You Were Paid All Accrued but Unpaid Wages ($16,958.33) and Accrued but Unused Vacation ($19,958.65), All Less Withholding, Irrespective of Whether You Sign the Agreement
12/34/56
EX-10.32
from 10-K 14 pages Employment Agreement
12/34/56